News

Acumen has entered a partnership, option and licence agreement with JCR for developing an oligomer-targeted EBD for Alzheimer’s disease.
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme.
Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek.